| Literature DB >> 35539862 |
Wenwen Zhao1,2, Zongyang Liu1,2, Weiwei Guo1,2, Kui Luo3, Jie Yang4, Wei Gao1,2, Xia Wu1,2, Xiaoqing Chen1,2.
Abstract
Ilexhainanoside D (IhD) and Ilexsaponin A1 (IsA) are a pair of oleanene- and ursane-type triterpenoid saponins, which are also the main bioactive pharmaceutical ingredients of Ilex hainanensis Merr. with great potential to treat non-alcoholic fatty liver disease (NAFLD). The pharmacokinetics of four representative triterpenoids in mice were investigated in this study, which were IhD, IsA and their major metabolites 3β, 19α-dihydroxyolean-12-ene-24, 28-dioic acid (ID) and Ilexgenin A (IA). A sensitive and accurate UPLC-MS/MS method was developed and validated for the simultaneous quantitative determination of IhD, IsA, ID and IA in control and NAFLD mice plasma after oral administration of the total saponins of I. hainanensis (the contents of IhD and IsA were 41.6% and 54.4%, respectively). The results revealed that the pharmacokinetic behaviors could be changed in NAFLD mice compared with control mice. The area under the plasma drug concentration-time curve and maximum plasma concentrations of IhD and IsA were greatly decreased in the NAFLD mice. However, the main residence time of ID and IA were greatly increased in the NAFLD mice. The results revealed that this method could be used to analyze two pairs of triterpenoid isomers in biological samples. This journal is © The Royal Society of Chemistry.Entities:
Year: 2018 PMID: 35539862 PMCID: PMC9078533 DOI: 10.1039/c8ra00739j
Source DB: PubMed Journal: RSC Adv ISSN: 2046-2069 Impact factor: 4.036
Fig. 1Product ion scan spectra of [M − H]− for (A) ilexhainanoside D, (B) ilexsaponin A1, (C) 3β, 19α-dihydroxyolean-12-ene-24, 28-dioic acid, (D) ilexgenin A and (E) saikosaponin A.
Fig. 2Chromatograms of blank plasma sample spiked with IhD, IsA, ID and IA prepared by protein precipitation (A) and LLE (B). (1) IhD and IsA, (2) ID and IA.
Fig. 3Typical chromatograms of blank plasma (A), blank plasma sample spiked with IhD, IsA, ID and IA at LLOQ and IS (B), plasma sample collected at 36 h after oral administration of IhS (C) and reference substance (D). (1) IhD and IsA, (2) ID and IA (3) IS.
Matrix effects and the extraction recoveries of the four analytes in mice plasma (n = 6)
| Analytes | Spiked-concentration (ng mL−1) | Matrix effects (%) | RSD (%) | Recovery (%) | RSD (%) |
|---|---|---|---|---|---|
| Ilexhainanoside D | 1 | 101.10 | 4.38 | 92.88 | 7.18 |
| 50 | 103.42 | 8.59 | 80.20 | 4.43 | |
| 160 | 97.59 | 6.64 | 77.22 | 1.68 | |
| Ilexsaponin A1 | 1 | 107.58 | 5.60 | 88.99 | 5.53 |
| 50 | 105.76 | 3.96 | 86.25 | 7.21 | |
| 160 | 101.49 | 4.19 | 80.36 | 1.41 | |
| 3β,19α-dihydroxyolean-12-ene-24, 28-dioic acid | 20 | 96.50 | 6.20 | 78.44 | 1.83 |
| 50 | 107.81 | 3.54 | 89.31 | 6.77 | |
| 160 | 99.29 | 1.22 | 75.44 | 8.91 | |
| Ilexgenin A | 20 | 101.38 | 2.83 | 85.31 | 1.27 |
| 50 | 106.04 | 2.44 | 90.41 | 7.83 | |
| 160 | 105.89 | 6.59 | 79.44 | 9.08 |
Precision and accuracy of the four analytes in mice plasma (n = 6)
| Analytes | Spiked-concentration (ng mL−1) | Intra-run | Inter-run | ||||
|---|---|---|---|---|---|---|---|
| Measured (ng mL−1) | RSD (%) | RE (%) | Measured (ng mL−1) | RSD (%) | RE (%) | ||
| Ilexhainanoside D | 1 | 1.04 ± 0.12 | 11.79 | 3.86 | 1.02 ± 0.11 | 10.69 | 2.24 |
| 50 | 47.83 ± 1.50 | 3.13 | −4.33 | 48.26 ± 4.07 | 8.42 | 1.93 | |
| 160 | 148.94 ± 2.74 | 1.84 | −6.91 | 163.51 ± 12.42 | 7.60 | 2.19 | |
| Ilexsaponin A1 | 1 | 1.05 ± 0.12 | 11.26 | 4.68 | 1.06 ± 0.10 | 9.47 | 6.11 |
| 50 | 46.27 ± 2.83 | 6.11 | −7.45 | 48.74 ± 3.81 | 7.81 | 1.95 | |
| 160 | 143.95 ± 1.47 | 1.02 | −10.03 | 162.85 ± 14.56 | 8.94 | 1.78 | |
| 3β,19α-Dihydroxyolean-12-ene-24, 28-dioic acid | 20 | 18.04 ± 1.29 | 7.17 | −9.81 | 19.34 ± 1.77 | 9.17 | −3.29 |
| 50 | 49.13 ± 2.95 | 6.00 | −1.75 | 50.30 ± 3.86 | 7.67 | 2.01 | |
| 160 | 162.94 ± 11.21 | 6.88 | 1.83 | 167.11 ± 14.97 | 8.96 | 4.44 | |
| Ilexgenin A | 20 | 17.83 ± 1.77 | 9.94 | −10.85 | 19.46 ± 1.87 | 9.62 | −2.68 |
| 50 | 47.19 ± 2.59 | 5.50 | −5.62 | 49.06 ± 4.26 | 8.68 | 1.96 | |
| 160 | 158.38 ± 14.4 | 9.09 | −1.01 | 162.45 ± 13.96 | 8.59 | 1.53 | |
Stability of the four analytes in mice plasma (n = 3)
| Analytes | Spiked-concentration (ng mL−1) | Three freeze–thaw cycle | −20 °C for 1 month | 4 h at room temperature | Processed samples at 4 °C for 12 h | ||||
|---|---|---|---|---|---|---|---|---|---|
| Measured (ng mL−1) | RSD (%) | Measured (ng mL−1) | RSD (%) | Measured (ng mL−1) | RSD (%) | Measured (ng mL−1) | RSD (%) | ||
| Ilexhainanoside D | 1 | 1.01 ± 0.07 | 6.99 | 0.98 ± 0.07 | 6.78 | 1.04 ± 0.12 | 11.10 | 1.06 ± 0.11 | 10.75 |
| 50 | 50.39 ± 2.09 | 4.15 | 50.22 ± 5.46 | 10.88 | 51.93 ± 5.59 | 10.76 | 48.95 ± 4.56 | 9.31 | |
| 160 | 149.02 ± 7.91 | 5.31 | 164.68 ± 7.83 | 4.75 | 161.08 ± 12.81 | 7.95 | 152.27 ± 8.78 | 5.77 | |
| Ilexsaponin A1 | 1 | 1.00 ± 0.11 | 11.51 | 1.44 ± 0.20 | 13.73 | 1.06 ± 0.1 | 9.47 | 1.05 ± 0.08 | 7.67 |
| 50 | 51.07 ± 3.61 | 7.07 | 50.76 ± 6.92 | 13.63 | 49.28 ± 4.22 | 8.56 | 50.21 ± 2.04 | 4.07 | |
| 160 | 141.42 ± 5.11 | 3.62 | 162.22 ± 9.96 | 6.14 | 161.21 ± 14.7 | 9.12 | 141.68 ± 4.38 | 3.09 | |
| 3 | 20 | 21.53 ± 0.36 | 1.70 | 19.51 ± 2.57 | 13.17 | 20.4 ± 1.87 | 9.15 | 17.9 ± 0.67 | 3.73 |
| 50 | 48.60 ± 0.64 | 1.31 | 51.90 ± 5.82 | 11.21 | 55.69 ± 4.99 | 8.96 | 52.49 ± 3.05 | 5.81 | |
| 160 | 173.51 ± 9.26 | 5.34 | 163.92 ± 14.95 | 9.12 | 155.41 ± 5.55 | 3.57 | 154.65 ± 2.45 | 1.58 | |
| Ilexgenin A | 20 | 21.99 ± 0.89 | 4.03 | 19.27 ± 2.55 | 13.23 | 21.15 ± 2.24 | 10.57 | 18.17 ± 0.77 | 4.26 |
| 50 | 49.00 ± 3.49 | 7.12 | 52.30 ± 5.97 | 11.41 | 53.39 ± 4.19 | 7.85 | 50.59 ± 3.05 | 6.02 | |
| 160 | 178.85 ± 14.56 | 8.14 | 155.78 ± 15.13 | 9.72 | 156.18 ± 7.39 | 4.73 | 153.89 ± 1.2 | 0.78 | |
Biochemical characteristics of the control mice and the NAFLD mice (n = 6)a
| Parameters | Unit | Control mice | NAFLD mice |
|---|---|---|---|
| Body weight | g | 28.00 ± 1.99 | 45.24 ± 2.99** |
| Liver weight | g | 1.02 ± 0.12 | 1.45 ± 0.21** |
| Epididymal fat | g | 0.45 ± 0.10 | 2.38 ± 0.33** |
| Perirenal fat | g | 0.11 ± 0.02 | 1.02 ± 0.11** |
| TG | mmol L−1 | 0.70 ± 0.15 | 0.87 ± 0.17 |
| TC | mmol L−1 | 2.29 ± 0.25 | 3.62 ± 0.35** |
| LDL-c | mmol L−1 | 0.29 ± 0.07 | 0.57 ± 0.11** |
| HDL-c | mmol L−1 | 2.25 ± 0.25 | 3.77 ± 0.34 |
| ALT | U/L | 16.19 ± 4.56 | 91.43 ± 35.37** |
| AST | U/L | 48.70 ± 8.39 | 84.34 ± 20.05** |
* P < 0.05 vs. control group.
Fig. 4H&E stained cross-sections of representative liver tissues (magnification 200×). (A) The control mice (B) the NAFLD mice.
Fig. 5Mean plasma concentration–time curves for IhD (A), IsA (B), ID (C) and IA (D) in the control and NAFLD mice after oral administration of IhS. The smaller plots were the enlarged curves for 0–4 h. (n = 6).
Pharmacokinetic parameters of IhD, IsA, ID and IA after oral administration of IhS (n = 6)a
| Analytes | Group | Pharmacokinetic parameters | |||||||
|---|---|---|---|---|---|---|---|---|---|
| AUC(0−t) (ng mL−1 × h) | AUC(0−∞) (ng mL−1 × h) | MRT(0−t) (h) |
|
|
|
| CL | ||
| Ilexhainanoside D | Control | 239.90 | 259.64 | 17.02 | 16.42 | 1 | 24.27 | 8785.14 | 370.88 |
| NAFLD | 105.70 | 125.43 | 10.66 | 11.98 | 0.75 | 15.15 | 14 992.90 | 867.21 | |
| Ilexsaponin A1 | Control | 469.37 | 653.13 | 17.38 | 31.11 | 1 | 37.25 | 8139.84 | 181.37 |
| NAFLD | 133.86 | 150.60 | 13.62 | 13.34 | 0.083 | 21.78 | 16 745.73 | 869.81 | |
| 3 | Control | 300.24 | 317.77 | 12.97 | 8.48 | 0.083 | 17.33 | 3961.81 | 323.95 |
| NAFLD | 584.92 | — | 19.48 | — | 24 | 22.42 | — | — | |
| Ilexgenin A | Control | 421.13 | 464.70 | 13.08 | 10.22 | 8 | 24.02 | 4283.20 | 290.53 |
| NAFLD | 942.25 | — | 20.28 | — | 24 | 43.79 | — | — | |
**P < 0.01 vs. control group.